Recent findings from this laboratory suggest that the biological actions of placental lactogen (PL) in mammalian fetal tissues are mediated through binding of the hormone to a distinct and unique PL receptor. We have now purified this receptor from fetal and maternal sheep liver, characterized its binding to PL, growth hormone (GH), and prolactin (PRL), and determined its molecular weight by SDS-PAGE and by affinity cross-linking techniques. Soluble extracts containing specific, high-affinity (Kd 0.5 nM) PL binding activity were prepared by incubating ovine fetal and maternal liver microsomes with 1% Triton X-100. The detergent solubilized PL receptor was purified two-to threefold by ion-exchange chromatography and an additional twofold by gel exclusion chromatography on Sepharose 6B. The PL receptor was then purified 75,000-to 125,000-fold by affinity chromatography using a column of ovine PL (oPL) coupled to Affi-Gel 10. The molecular weight of the oPL receptor as determined by SDS-PAGE and by cross-linking techniques was 44,000 +/-2,000 (range 40,000-48,000). The purified receptor bound 125I-oPL specifically and with high affinity (Kd 0.5 nM) but did not bind either radiolabeled ovine GH or ovine PRL. In addition, in competition studies using 125I-oPL as the radioligand, the purified PL receptor bound unlabeled oPL with a potency 30-50 times greater than that of ovine GH and 500-1,000 times greater than that of ovine […] 
Introduction
Placental lactogen (PL)' is a polypeptide hormone that has structural and functional similarities to growth hormone (GH) and prolactin (PRL). Studies by many investigators during the past 25 yr suggested that PL functions predominantly or exclusively as a maternal hormone during pregnancy, exerting effects on maternal carbohydrate and lipid metabolism and the production ofinsulin-like growth factor I (1, 2). Recent studies from this and other laboratories, however, indicate that PL may also play a role in the regulation of fetal metabolism and the control of fetal growth. PL has direct anabolic effects on fetal amino acid and carbohydrate metabolism (3) (4) (5) (6) (7) (8) and stimulates ornithine decarboxylase activity (9) , DNA synthesis (10, 11) , and somatomedin production (10, 12, 13) in fetal tissues. In contrast, most studies demonstrate that GH and PRL have little or no somatotropic activity in the fetus (3, 9, 12, (14) (15) (16) (17) . Since the biological effects of PL in fetal tissues are similar to those of GH in postnatal tissues, PL appears to function as a "fetal GH."
Previous investigators postulated that the biological actions of PL in tissues of postnatal animals are mediated through binding of the hormone to GH (somatotropic) or PRL (lactogenic) receptors (18) (19) (20) (21) . Studies from this laboratory, however, strongly suggest that the biological actions of PL in fetal tissues are mediated through binding of the hormone to a distinct and unique PL receptor. The specific binding of radiolabeled PL to ovine fetal liver (8, 22, 23) and to human fetal skeletal muscle (24) greatly exceeds that ofradiolabeled GH or PRL, and PL binding sites in ovine and human fetal tissues have high affinity for PL and low affinity for GH and PRL. In addition, the molecular weight of the PL binding site in fetal sheep liver (38,000-47,000 mol wt) as determined by affinity cross-linking techniques (23) differs from that ofthe GH binding site in postnatal sheep liver (54,000/118,000 mol-wt). These findings suggest that PL receptors in fetal tissues differ in structure and function from GH and PRL receptors in postnatal tissues.
In recent investigations (25) we demonstrated that treatment of sheep liver microsomes with Triton X-100 solubilizes the PL binding site but not the GH binding site. We have exploited this differential solubilization of PL and GH binding sites in order to purify the PL receptor from fetal and maternal liver. We have characterized the binding of the purified receptor to PL, GH, and PRL and have determined its molecular weight by SDS-PAGE and by affinity cross-linking techniques.
Methods
Hormones. Ovine placental lactogen (oPL, lot 3-23) was prepared from sheep cotyledons as previously described (26) . Ovine growth hormone (oGH, NIH-GH-S12) and ovine prolactin (oPRL, NIH-P-S14) were obtained from the National Hormone and Pituitary Program, National Institute of Arthritis, Digestive Disease and Kidney. The prepa-Preparation of radiolabeled hormones. '25I-oPL, '25I-oGH, and '25I-oPRL were prepared using 1,3,4,6-tetrachloro 3,6-diphenyl glycouril (Iodo-Gen, Pierce Chemical Co., Rockford, IL) as the catalyst, as previously described (8, 22, 23) . Each preparation of '25I-oPL and '25I-oGH exhibited > 25% specific binding to hepatic membranes from lactating rabbits at 20 h of incubation at 40C using 250 gg of hepatic membrane protein per assay tube (20) . Each preparation of '25I-oPRL exhibited > 20% specific binding to rabbit mammary tissue under similar conditions (19 The oPL-Affi-Gel (2.5 ml) was incubated with the pooled Sepharose eluate (total volume 16 ml in Tris-Triton) for 24 h at 40C in the presence of 10 mM MgCl2, 20 IU/ml aprotinin and 0.1 mM PMSF. After this incubation, the oPL-Affi-Gel was washed with 600 ml ofcold Tris-Triton and poured into a 5 X 1.5 cm column. Protein bound to the affinity column was then eluted with 6 ml ofTris-Triton containing 5 M MgCl2 at 23°C. l-ml fractions were collected on ice and then dialyzed at 4°C against Tris-Triton. Fractions containing oPL binding activity were pooled and stored at -700C. 4 min, the contents of the tube were removed and analyzed by SDS-PAGE.
SDS-PAGE. Samples containing the iodinated oPL receptor were boiled for 5 min in electrophoresis sample buffer (60 mM Tris-HCl, pH 6.8, containing 3% SDS, 10% glycerol, 6 M urea, 0.001% bromphenol blue, with or without 5% f3-mercaptoethanol). The mixtures were centrifuged at 3,000 g for 5 min and the samples were then analyzed on a 12.5% polyacrylamide gel using the discontinuous buffer system described by Laemmli (28) at a constant 70 V for 18 h. After drying, the gels were autoradiographed at -70°C using Kodak XAR-2 film and an enhancing screen. The apparent molecular weights of the radiolabeled proteins were determined by comparison with the relative migration of prestained molecular weight standards which had been applied to the gel (myosin 200,000; a-macroglobulin, 180,000; fl-galactosidase, 116,000; fructose-6-phosphate kinase, 84,000; pyruvate kinase, 58,000; fumarase, 48,500, lactate dehydrogenase, 36,500; and triosephosphate isomerase, 26,600, Sigma Chemical Co., St.
Louis, MO).
In order to analyze the noniodinated, affinity-purified receptor by SDS-PAGE, it was necessary to concentrate active fractions and thereby maximize the recovery of protein. A 2-ml aliquot of affinitypurified receptor in Tris-Triton was concentrated by ultrafiltration on a Centricon microconcentrator (10,000-mol wt cutoff, Amicon Corp.). The concentrated sample (50-100 Ml) was dialyzed against 200 vol of Tris-Triton, boiled in electrophoresis sample buffer, and analyzed on a 12.5% polyacrylamide gel as described in the preceding paragraph. The gel was stained with silver using the method of Oakley et al. (29) . The molecular weight of the stained protein was estimated by comparing its migration on the gel with that of prestained molecular weight standards. The quantity of purified receptor applied to the gel was estimated by comparing the intensity of the staining of the receptor with that of the molecular weight standard using a densitometer.
Cross-linking of the purified receptor to radiolabeled oPL. Crosslinking was performed by a modification of the method of Spencer et al. (30) . Affi-Gel eluates containing oPL binding activity were dialyzed against 25 mM Hepes, 10 mM MgCI2, pH 7.6. Aliquots ofthe dialyzed receptor were incubated for 24 h at 40C with '25I-oPL (500,000 cpm, 0.5 nM) in the presence or absence of excess (1I g) unlabeled oPL.
Hormone-receptor complexes were then precipitated with polyethylene glycol as described previously (25 
Results
Soluble extracts of fetal and maternal liver were prepared by incubating sheep hepatic microsomes with 1% Triton X-100 in Tris buffer. Detergent extracts prepared in this manner contained specific, high-affinity (Kd 0.5 nM) PL binding activity but little or no specific GH or prolactin binding activity (25) .
The PL receptor was purified from the detergent extracts by ion-exchange chromatography, size exclusion chromatography, and affinity chromatography. The various chromatographic procedures yielded qualitatively similar results with extracts of fetal or maternal liver (Tables I and II) . Chromatography ofsoluble Triton extracts on DE-52 at pH 8.0 provided a two-to threefold purification of the PL receptor, and chromatography of the DE-52 eluate on Sepharose 6B provided an additional twofold purification. The PL receptor was eluted from Sepharose 6B as a broad peak of binding activity with an approximate molecular weight of 130,000 (Fig. 1) . The overall recoveries of fetal and maternal oPL binding activity from DE-52 and Sepharose 6B were 75-81% and 47-53%, respectively. After ion-exchange and size-exclusion chromatography, the PL receptor was purified 75,000-to 125,000-fold by affinity chromatography using a column of ovine PL coupled to Affi-Gel 10. Soluble extracts of fetal and maternal liver were incubated with oPL-Affi-Gel for 24 h at 4VC, and material which had bound to the affinity column was eluted with buffer containing 5 M MgCl2. Fractions were dialyzed against TrisTriton and then assayed for specific oPL binding activity. As shown in Fig. 2 , the oPL receptor bound to the oPL affinity column and was eluted with 5 M MgCl2. The overall recovery ofoPL binding activity following ion-exchange, Sepharose and affinity chromatographies was 16-30%; a higher recovery might have been obtained if we had used more than 1 mg of oPL in the generation of the affinity column.
When Affi-Gel fractions containing oPL binding activity were concentrated and analyzed by SDS-PAGE, the predominant protein observed had a molecular weight of 44,000±2,000 (Fig. 3) . The presence of j3-mercaptoethanol in the electrophoresis sample buffer did not alter the apparent molecular weight of the protein. When Affi-Gel fractions containing oPL binding activity were Spaoe B eh fraction number (1 ml) on Sepharose 6B. Sepharose fractions containing oPL binding activity were pooled and incubated with oPL-Affi-Gel under the conditions described in Methods. The affinity column was then washed with 600 ml of cold Tris-Triton, and material which had bound to oPLAffi-Gel was eluted with Tris-Triton containing 5 M MgCl2. Affi-Gel fractions were dialyzed against Tris-Triton and assayed for oPL binding activity. Values represent the mean of triplicate values. In each case, the SE was < 15% of the mean value. Similar findings were noted using soluble extracts of maternal and fetal liver at 133 d of gestation.
by SDS-PAGE, a single protein band with 43,000 mol wt was observed (Fig. 4 , lanes F and Ml). To determine whether this 43,000-mol wt protein represented the oPL receptor, fractions containing the iodinated protein were subjected to affinity chromatography a second time and analyzed by SDS-PAGE. Under these conditions, a radiographic band with 43,000 mol wt was also observed (Fig. 4, lane M2) , suggesting that the ibdinated protein contained PL binding activity.
Affi-Gel fractions containing the 44,000-mol wt protein bound '25_-oPL specifically and with high affinity (Kd 0.6 nM, Fig. 5 , inset) but did not specifically bind radiolabeled oGH or oPRL in parallel experiments. The specific binding of radiolabeled oPL in experiments using 120 ,l of the dialyzed MgCl2 eluate (estimated to contain 2.5-5 ng of the 44,000-mol wt protein) was 4.5-6.0%. In experiments using 350 1l of the dialyzed MgCl2 eluate, the specific binding ofradiolabeled oPL was as high as 16%. In competition studies using I251-oPL as the radioligand (Fig. 6) , the potency of oPL in competing for binding to the purified oPL receptor greatly exceeded that of oGH or oPRL. The PL receptor bound unlabeled oPL with a potency 30-50 times greater than that of oGH and 500-1,000 times greater than that of oPRL. Epidermal growth factor (500 ng/ml) and insulin (1 ,uM) did not compete with '25I-oPL in the binding assay.
Cross-linking of 125I-oPL to the affinity-purified receptor yielded a radioactive protein complex with molecular weight Triton, boiled in electrtphoresis sample buffer, and analyzed on a 12.5% polyacrylamide gel under nonreducing (M) or reducing (F) conditions. The gels were stained with silver, and the molecular weights of the stained proteins were estimated by comparison with molecular weight standards applied to the gel. Estimates of the molecular weight of the oPL receptor using extracts of fetal and maternal liver at 131 and 133 d of gestation ranged from 40,000 to 48,000. 67,000 (Fig. 7, lane 1) . The 67,000-mol wt radioactive complex was not observed when incubations were performed in the presence of a 1000-fold excess of unlabeled oPL (Fig. 7, lane  2) . Since the molecular weight of oPL is -22,000, the molecular weight of the oPL receptor estimated by affinity crosslinking was -45,000.
Discussion
We have purified a 44,000±2,000-mol wt protein from soluble detergent extracts of fetal and maternal sheep liver. Five lines of evidence suggest that this 44,000-mol wt protein is the PL receptor or a component of the PL receptor: first, Affi-Gel fractions that contained predominantly the 44,000-mol wt protein bound radiolabeled oPL specifically and with high affinity but did not specifically bind radiolabeled oGH or oPRL; secondly, Affi-Gel fractions containing the 44,000-mol wt protein, like microsomal fractions of ovine fetal liver (22, 23), bound oPL with a potency 30-50 times greater than that of oGH and 500-1,000 times greater than that of oPRL; thirdly, the iodinated 44,000-mol wt protein re-bound to the oPL affinity column; fourthly, cross-linking of radiolabeled oPL to fractions containing the 44,000-mol wt protein yielded a radioactive hormone-receptor complex with a molecular weight of 67,000, indicating that the 44,000-mol wt protein contained specific oPL binding activity; and fifthly, the molecular weight of the purified PL receptor (44,000±2,000) is similar or identical to that of the oPL binding site in sheep liver microsomes (38,000-47,000) determined previously (23, 25) by affinity cross-linking techniques. The molecular weight of the PL receptor estimated by Sepharose chromatography was higher (130,000) than that estimated by SDS-PAGE because the receptor may have migrated on Sepharose as a component of a Triton-protein micelle.
Whereas the PL receptor has an apparent molecular weight of 44,000±2,000, the GH receptor detected in human adult liver (34) and in tissues of postnatal rabbits (30, 34) , rats (35, 36) , mice (37) , and sheep (23, 25) has a molecular weight of 108,000-130,000 (34) . A GH binding site of lower molecular weight (50,000-80,000) identified in rabbit (38, 39) and sheep (23, 25) liver and in rabbit (38) and human (40, 41) serum appears to represent the extracellular GH-binding domain cleaved from the GH receptor by proteolysis at or near the receptor transmembrane region (30, 34) . While the molecular weight of the PL receptor differs from that of the GH receptor, the molecular weight of the PL receptor is similar to that of prolactin receptors (32,000-41,000) purified from rabbit mammary gland (42) and rat liver (43) . In addition, the PL 1-) (±) (24) , the PL receptor purified from sheep liver has high affinity for PL (Kd 0.5 nM) but low affinity for GH and PRL. In contrast, GH (somatotropic) receptors in the sheep and in other mammals have high affinity for the mammalian growth hormones and the ovine and caprine placental lactogens but low affinity for the mammalian PRLs and the primate PLs (18, 20, 21) . PRL (lactogenic) receptors preferentially bind prolactin and other "lactogenic" hormones such as human GH and human PL but have low affinity for "somatotropic" hormones such as oGH and bovine GH (18, 19) .
The PL, GH, and PRL receptors are also distinguished by striking differences in expression during ontogeny. Specific PL binding sites are detected in the liver of the fetal lamb (8, 22, 23, 25) and fetal mouse (45) and in the liver and skeletal muscle ofthe human fetus (24) . In contrast, there is little or no specific binding of radiolabeled GH or PRL to human fetal skeletal muscle (24) or to tissues of the fetal rat, rabbit, rhesus monkey, mouse, or sheep (8, 22, (46) (47) (48) (49) (50) . Specific GH binding sites are detected in low concentrations in microsomal fractions of human fetal liver (24) . After birth, the binding of GH to human liver and to other mammalian tissues increases markedly (8, 21, 22, 46, 47, 50) .
Changes in the expression of PL and GH receptors may mediate changes in the hormonal control ofgrowth during the transition from fetal to postnatal life. The presence of distinct PL receptors in fetal tissues provides a mechanism whereby PL may exert direct anabolic effects on fetal amino acid and carbohydrate metabolism and may stimulate fetal somatomedin production. On the other hand, GH does not acquire somatotropic activity until a new and distinct GH receptor emerges after birth. Since the biological actions of PL in fetal tissues are similar to the effects ofGH in postnatal tissues, the presence of distinct fetal PL receptors implicates a role for PL as a "fetal GH."
A role for PL as a "maternal GH" during pregnancy is suggested by studies demonstrating that PL has GH-like effects on carbohydrate and lipid metabolism and stimulates insulinlike growth factor I production in pregnant rats (1, 2, 5 1). Our studies in the sheep indicate that maternal liver contains both PL and GH receptors. Since oPL binds with high affinity to GH as well as PL receptors, the biological actions of PL in tissues of the pregnant sheep may be mediated through binding to PL and/or GH receptors.
In summary, we have purified and characterized a distinct PL receptor, a new member of the GH/PRL receptor family. The PL receptor differs from previously characterized somatotropic (GH) and lactogenic (PRL) receptors in structure, function, and expression during ontogeny and may play a role in the regulation of maternal metabolism and the control of fetal growth.
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